Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis.

Autor: Salunke AA; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India. Electronic address: drabhijeetsalunke@gmail.com., Nandy K; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Pathak SK; Department of Orthopedics, MMIMSR, M M Deemed to be University, Mullana, Ambala, India., Shah J; Department of Orthopedic Oncology, Osteocare Ortho Onco Clinic, Ahmedabad, Gujarat, India., Kamani M; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Kottakota V; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Thivari P; Department of Orthopedics, MMIMSR, M M Deemed to be University, Mullana, Ambala, India., Pandey A; Department of Radiation Oncology, MMIMSR, MM Deemed to be University, Ambala, Haryana, India., Patel K; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Rathod P; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Bhatt S; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Dave P; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India., Pandya S; Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2020 Sep - Oct; Vol. 14 (5), pp. 1431-1437. Date of Electronic Publication: 2020 Jul 28.
DOI: 10.1016/j.dsx.2020.07.037
Abstrakt: Background and Aimsbackground: Currently there is limited knowledge on cancer and COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of cancer on serious events including ICU admission rate and mortality in COVID 19.
Methods: PubMed, Cochrane Central Register of Clinical Trials were searched on April 16, 2020, to extract published articles that reported the outcomes of cancer in COVID-19 patients. The search terms were "coronavirus" and "clinical characteristics" with no language or time restrictions. We identified 512 published results and 13 studies were included in the analysis.
Results: There were 3775 patients, of whom 63 (1·66%) had a cancer. The pooled estimates of ICU admission in COVID 19 patients with and without cancer were 40% versus 8·42%.The odds ratio of ICU admission rates between the cancer and non-cancer groups was 2.88 with a 95% CI of 1·18 to 7·01 (p = 0·026). The pooled estimates of death rate in COVID -19 patients with and without cancer were 20·83% versus 7·82%. The odds ratio of death rates between the cancer and non-cancer groups was 2.25 with a 95% CI ranging from 0·71 to 7·10 with p value of 0·166. The pooled prevalence of cancer patients was 2% (95 CI 1-4).
Conclusions: Presence of cancer in COVID-19 leads to higher risk of developing serious events i.e. ICU admission, mechanical ventilation and mortality. The presence of cancer has a significant impact on mortality rate in COVID-19 patients.
Competing Interests: Declaration of competing interest Nothing to declare.
(Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: